Merck & Company, Inc. (NYSE:MRK) was the recipient of unusually large options trading activity on Friday. Traders acquired 20,366 put options on the stock. This represents an increase of 520% compared to the typical daily volume of 3,284 put options.
A number of institutional investors have recently bought and sold shares of MRK. WFG Advisors LP raised its position in Merck & by 16.9% in the second quarter. WFG Advisors LP now owns 13,478 shares of the company’s stock valued at $864,000 after buying an additional 1,946 shares during the last quarter. Toronto Dominion Bank increased its stake in shares of Merck & by 22.4% in the second quarter. Toronto Dominion Bank now owns 1,019,846 shares of the company’s stock worth $65,359,000 after buying an additional 186,774 shares during the last quarter. Afam Capital Inc. increased its stake in shares of Merck & by 14.5% in the second quarter. Afam Capital Inc. now owns 36,755 shares of the company’s stock worth $2,356,000 after buying an additional 4,667 shares during the last quarter. Beaton Management Co. Inc. purchased a new stake in shares of Merck & during the second quarter worth about $1,143,000. Finally, Fort Pitt Capital Group LLC increased its stake in shares of Merck & by 2.5% in the second quarter. Fort Pitt Capital Group LLC now owns 22,061 shares of the company’s stock worth $1,414,000 after buying an additional 541 shares during the last quarter. Institutional investors own 73.46% of the company’s stock.
Shares of Merck & (MRK) traded down 0.57% during midday trading on Friday, hitting $61.49. 8,421,689 shares of the stock traded hands. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80. The stock has a market capitalization of $167.71 billion, a P/E ratio of 33.29 and a beta of 0.80. The firm has a 50-day moving average price of $62.91 and a 200-day moving average price of $63.83.
Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The firm had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. During the same quarter in the prior year, the business posted $0.93 EPS. The business’s revenue was up .9% compared to the same quarter last year. On average, equities analysts predict that Merck & will post $3.87 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 3.06%. Merck &’s payout ratio is 76.11%.
Several research firms have weighed in on MRK. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. HSBC Holdings plc raised shares of Merck & from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 9th. UBS AG lifted their target price on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reaffirmed a “buy” rating and issued a $74.00 price objective on shares of Merck & in a research note on Tuesday, June 6th. Finally, Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $69.58.
TRADEMARK VIOLATION WARNING: This piece of content was first published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/investors-buy-large-volume-of-put-options-on-merck-nysemrk-updated-updated-updated.html.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.